8-K: Dyadic International Faces Nasdaq Delisting Threat

Dyadic International, Inc. received a Nasdaq deficiency notice for failing to meet continued listing requirements, including minimum stockholders' equity.

Summary

• Dyadic International, Inc. (DYAI) received a deficiency notice from Nasdaq on March 27, 2026, indicating non-compliance with Nasdaq Listing Rule 5550(b) for continued listing.
• The company failed to meet at least one of the following requirements: $2.5 million in stockholders' equity, $35 million in market value of listed securities, or $500,000 of net income from continuing operations.
• This notice does not immediately affect the listing of the company's common stock on the Nasdaq Capital Market.
• Dyadic has 45 calendar days, until May 11, 2026, to submit a plan to regain compliance with the Continued Listing Requirement.
• If the plan is accepted, the company may be eligible for a cure period of up to 180 days from March 27, 2026 (until September 23, 2026).
• The company also remains non-compliant with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and has until June 17, 2026, to regain compliance for this separate deficiency.
• Failure to cure either deficiency by the applicable deadline could result in the delisting of the company's common stock.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development, as the company faces two separate Nasdaq listing deficiencies, both carrying the risk of delisting, which could severely impact investor confidence and access to capital.

Negatives

• Receipt of a deficiency notice from Nasdaq on March 27, 2026, for non-compliance with Nasdaq Listing Rule 5550(b) regarding continued listing requirements.
• Failure to maintain at least $2.5 million in stockholders' equity, $35 million in market value of listed securities, or $500,000 of net income from continuing operations.
• The company remains out of compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)), with a deadline of June 17, 2026.
• Either deficiency, if not cured by the respective deadlines, could be a basis for the delisting of the company's common stock from Nasdaq.

Risks

• History of net losses.
• Market and regulatory acceptance of microbial protein production platforms and other technologies.
• Failure to commercialize microbial protein production platforms or other technologies.
• Competition, including from alternative technologies.
• Results of nonclinical studies and clinical trials.
• Capital needs.
• Changes in global economic and financial conditions.
• Reliance on information technology.
• Dependence on third parties.
• Government regulations and environmental, social, and governance issues.
• Intellectual property risks.
• Inability to comply with the listing standards of the Nasdaq, potentially leading to delisting.

Future Outlook

The company intends to actively monitor its compliance with the Continued Listing Requirement and plans to evaluate available options to resolve the deficiency and regain compliance, likely through the $2.5 million stockholders' equity requirement. There is no assurance that an appeal to Nasdaq would be successful if a compliance plan is not accepted. Forward-looking statements also cover expectations regarding clinical trials, protein production platforms, research projects, third-party collaborations, and the availability of necessary funding.

Management Comments

• "The Company intends to actively monitor its compliance with the Continued Listing Requirement an ongoing basis and, as appropriate, plans to evaluate available options to resolve the deficiency and regain compliance (likely through the $2.5 million in stockholders equity requirement)."

Industry Context

StockSavvy.ai notes that small-cap biotechnology companies, particularly those in early development stages like Dyadic, frequently face challenges in maintaining Nasdaq listing requirements, especially regarding minimum bid price and financial metrics like stockholders' equity, due to ongoing R&D expenses and limited revenue generation. This situation is not uncommon for companies reliant on future commercialization success and external funding.

Comparison to Industry Standards

• Maintaining Nasdaq listing requirements, such as minimum stockholders' equity ($2.5 million), market value ($35 million), or net income ($500,000), is a fundamental standard for publicly traded companies. Dyadic's non-compliance indicates a deviation from these basic benchmarks.
• The $1.00 minimum bid price is a common hurdle for smaller companies, often leading to reverse stock splits or delisting if not addressed. Companies like Sorrento Therapeutics (SRNEQ) and Athersys (ATHX) have faced similar challenges with bid price and listing compliance.

Stakeholder Impact

• Shareholders: Significant negative impact due to increased risk of delisting, which could lead to reduced liquidity, lower share price, and potential loss of investment if the stock moves to OTC markets.
• Creditors: May view the company as higher risk, potentially impacting future borrowing terms or access to credit.
• Employees: Uncertainty regarding the company's future listing status could affect morale and retention.

Next Steps

• Submit a plan to Nasdaq to regain compliance with Rule 5550(b) by May 11, 2026.
• Actively monitor compliance with the Continued Listing Requirement.
• Evaluate available options to resolve the deficiency, likely targeting the $2.5 million stockholders' equity requirement.
• Regain compliance with the $1.00 minimum bid price requirement by June 17, 2026.
• Potentially appeal Nasdaq's determination to a hearings panel if the compliance plan is not accepted.

Key Dates

Recommendation

The company faces two distinct Nasdaq listing deficiencies, including a new one related to fundamental financial health (stockholders' equity, market value, or net income) and a persistent minimum bid price issue. The risk of delisting is high, which would severely impair liquidity and investor confidence. While the company plans to address these, the cumulative nature of the deficiencies and the short timelines present significant downside risk, making it a strong sell for investors seeking stability and compliance.

Keywords

Dyadic International, DYAI, Nasdaq, delisting, deficiency notice, listing requirements, stockholders equity, minimum bid price, biotechnology, protein production, SEC filing, 8-K